About US
Contact us
-
It's official: The Pfizer-AstraZeneca deal talk can resumeLet the speculation continue: The window to another Pfizer-AstraZeneca bidding round is now open, per U.K. takeover rules. As of Tuesday, AstraZeneca ($AZN) can legally invite Pfizer ($PFE) to negotia2014/8/27
-
PHEXCOM Events &Advertisement Cooperation 2015For the sake of providing better service to satisfy your demand, we prepared the “PHEXCOM Events and ADCooperation 2015”. More information please find the attachment. 1.5thPHEXFEST/China Pharmaceutic2014/8/26
-
Talk gets fevered over whether Pfizer, J&J or Lilly might make a run at CubistThe announcement that the FDA will review a second drug candidate from antibiotic specialist Cubist Pharmaceuticals ($CBST), speculation is ramping up that it is ripe for a takeover. Pfizer ($PFE), wh2014/8/25
-
GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the USA for the treatment of asthma20 August 2014 GlaxoSmithKline plc today announced that the Food and Drug Administration has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled cortico2014/8/25
-
Roche negotiating for rest of Chugai for $10BA year ago, CEO Schwan said there was no need to buy the 40% it didn't own Just last month Roche CEO Severin Schwan indicated he wasn't interested in mega-deals to build his company, only smaller, mo2014/8/22
-
2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 5nd station--Changchun2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 5nd station--Changchun, was successfully concluded on August 7 at Jindu Hotel . More than 90 technical persons from 20 ph2014/8/21
-
2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 4nd station--Tonghua2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 4nd station--Tonghua, was successfully concluded on August 5 at East Holiday Hotel . More than 90 technical persons from2014/8/20
-
Docs to FDA: Biosimilars should have different names than branded drugsEver since theFDAdrafted a set of rules forbiosimilarsin 2012, a debate has been raging over whether those drugs should carry the same generic names as the products they emulate. Now, some doctors are2014/8/19
-
Biogen ready to steal market share with newly minted MS drug PlegridyBiogen Idec ($BIIB) has added another bow to itsmultiple sclerosisquiver. With the FDA's approval of Plegridy, a long-acting form of its popular Avonex, Biogen can fight for an even bigger share of th2014/8/19
-
Roche's Avastin nabs quick FDA nod for cervical cancer useAfter promising last month to fast track its review of Roche's ($RHHBY) Avastin in cervical cancer, the FDA has come back with a positive verdict--a full two months before its deadline. The agency app2014/8/18